Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation
J Brognard, AS Clark, Y Ni, PA Dennis - Cancer research, 2001 - AACR
To evaluate the role of Akt/PKB in non-small cell lung cancer (NSCLC) survival, we analyzed
NSCLC cell lines that differed in tumor histology as well as p53, Rb, and K-ras status. …
NSCLC cell lines that differed in tumor histology as well as p53, Rb, and K-ras status. …
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells
AS Clark, K West, S Streicher, PA Dennis - Molecular cancer therapeutics, 2002 - AACR
To evaluate the role of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in breast cancer
cell survival and therapeutic resistance, we analyzed a panel of six breast cancer cell lines …
cell survival and therapeutic resistance, we analyzed a panel of six breast cancer cell lines …
[HTML][HTML] Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells
KA West, J Brognard, AS Clark… - The Journal of …, 2003 - Am Soc Clin Investig
Tobacco-related diseases such as lung cancer cause over 4.2 million deaths annually, with
approximately 400,000 deaths per year occurring in the US. Genotoxic effects of tobacco …
approximately 400,000 deaths per year occurring in the US. Genotoxic effects of tobacco …
[HTML][HTML] Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
…, B Chen, AJ Chien, SY Chui, AS Clark… - The Lancet …, 2022 - thelancet.com
Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …
Clinical diagnosis and management of breast cancer
ES McDonald, AS Clark, J Tchou, P Zhang… - Journal of Nuclear …, 2016 - Soc Nuclear Med
The diagnosis and management of breast cancer are undergoing a paradigm shift from a
one-size-fits-all approach to an era of personalized medicine. Sophisticated diagnostics, …
one-size-fits-all approach to an era of personalized medicine. Sophisticated diagnostics, …
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast …
M Cuello, SA Ettenberg, AS Clark, MM Keane… - Cancer research, 2001 - AACR
We investigated whether combined treatment with tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) and trastuzumab could enhance the specific killing of cells that …
ligand (TRAIL) and trastuzumab could enhance the specific killing of cells that …
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
A DeMichele, AS Clark, KS Tan, DF Heitjan… - Clinical Cancer …, 2015 - AACR
Purpose: The G 1 –S checkpoint of the cell cycle is frequently dysregulated in breast cancer.
Palbociclib (PD0332991) is an oral inhibitor of CDK4/6. Based upon preclinical/phase I …
Palbociclib (PD0332991) is an oral inhibitor of CDK4/6. Based upon preclinical/phase I …
Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer
…, RH Pierce, JM Matro, AM DeMichele, AS Clark… - Cancer immunology …, 2017 - AACR
Chimeric antigen receptors (CAR) are synthetic molecules that provide new specificities to T
cells. Although successful in treatment of hematologic malignancies, CAR T cells are …
cells. Although successful in treatment of hematologic malignancies, CAR T cells are …
Characteristics associated with differences in survival among black and white women with breast cancer
JH Silber, PR Rosenbaum, AS Clark, BJ Giantonio… - Jama, 2013 - jamanetwork.com
Importance Difference in breast cancer survival by race is a recognized problem among
Medicare beneficiaries. Objective To determine if racial disparity in breast cancer survival is …
Medicare beneficiaries. Objective To determine if racial disparity in breast cancer survival is …
[PDF][PDF] Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib added to
standard paclitaxel neoadjuvant chemotherapy (durvalumab/olaparib/paclitaxel [DOP]) was …
standard paclitaxel neoadjuvant chemotherapy (durvalumab/olaparib/paclitaxel [DOP]) was …
